Printer Friendly

AUSTCANCER APPOINTS SINGAPORE DISTRIBUTOR FOR REVISYS.

Australian Cancer Technology Limited ("AustCancer") (ASX: ACU) has announced that its US subsidiary, ACT (USA) Inc, has appointed Hengzi Technology Investment Pte Ltd as exclusive distributor of the revisys range of nutritional supplements in Singapore. This is the first distribution deal for the products in a market outside the United States.

Hengzi Technology is a specialist supplier to health professionals in the Asia Pacific region where it markets and distributes a range of medical devices and pharmaceutical products on behalf of a number of prominent international healthcare companies. The company is in partnership with VRI BioMedical, an Australian biotechnology company, in establishing its Gastointestinal Health Products in S.E. Asia & South Asia.

Hengzi Technology director, Lim Linbert, sees the revisys range satisfying a growing need in the Singapore market for premium nutritional supplements. "Most western medicine patients in Singapore would also seek complementary medicines for their conditions. There is an increasing call for complementary products that are backed by sound medical science," Lim said.

Revisys is an integrated, multi-level nutrient system that provides support for four levels of health and nutritional needs, from general well-being to condition-specific supplementation. It is particularly designed for patients facing unique nutritional requirements due to extenuating health issues. Developed by leading medical scientists and launched in the United States in February this year, revisys aims to become the leading choice of medical professionals for scientifically credible, high quality nutritional supplements.

AustCancer managing director Paul Hopper said, "We've made good early progress in penetrating the United States market with revisys and we are now ready to start developing a position in other markets. Singapore intrinsically appeals as a strong potential market for us and if it meets our expectations, expansion into other Asian countries would be a logical next step."

The revisys products will be launched into the Singapore market in November this year. The products' developers, the prominent US medical scientists Professor David Felten and Professor Barry Boyd, will introduce revisys in a series of presentations to Singapore oncologists and other health professionals. The critical success factor is to convince Medical practitioners in Singapore that revisys products and value proposition are superior.

Product for the Singapore market will be manufactured by ACT (USA) in Australia, where plans are also underway to launch revisys by December 2004

ACT (USA) has estimated that total (domestic and export) sales of revisys will be of the order of US$8-10 million pa by 2006.

For more information, call 585-419-9710.

Australian Cancer Technology

Australian Cancer Technology is a broadly based international oncology company developing a portfolio of high quality oncology-related projects that are at various stages of commercialization. Cash generating businesses will provide the funds to exploit the potential of its leading products and to introduce promising pre-clinical and Phase I projects into the development pipeline. Its leading edge Pentrys anti-cancer vaccine successfully completed Phase I and Phase I/IIa trials at St. Vincent's Hospital Sydney and is undergoing a comprehensive Phase IIb trial with prostate cancer patients at three leading Melbourne institutions. Its US subsidiary, revisys, is launching a range of nutritional supplements designed by leading US scientists for people with special needs, including those undergoing cancer treatment. The company is also broadening its cancer therapeutic development pipeline and has recently announced the acquisition of US based Galenica Pharmaceuticals, whose immune enhancing products are being used in three Phase I cancer vaccine trials and will be used in a number of other forthcoming clinical trials in association with Memorial Sloan Kettering Cancer Centre in New York and The University of Alabama. AustCancer has completed a Level 1 ADR program on NASDAQ (AUCJY).

For more information, visit http://www.austcancer.com.au and http://www.revisyshealth.com.
COPYRIGHT 2004 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Worldwide Biotech
Geographic Code:8AUST
Date:Sep 1, 2004
Words:617
Previous Article:UNIGEN/INCA HEALTH TO DEVELOP PLANT-DERIVED HEALTH PRODUCTS.
Next Article:KINEXUS VALIDATES PLK1 AS CANCER DRUG TARGET.
Topics:


Related Articles
Anglican imports. (Schism).
Wise signs distribution deals in Asia.
US ONCOLOGY CENTER OFFERS AUSTCANCER'S REVISYS SUPPLEMENTS.
Toma[h.sup.3].
AUSTCANCER TO ACQUIRE U.S. VACCINE DEVELOPER.
Market with good results gets mixed reviews.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters